참고문헌
- Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Statistics 1999;10(200):1-212.
- Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1) 55-78. https://doi.org/10.1016/0049-0172(73)90009-7
- Sege-Peterson K, Winchester R. Psoriatic arthritis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill; 1999522-33.
- Gladman DD. Psoriatic arthritis. Rheum Dis Clin North Am 1998;24:829-44. https://doi.org/10.1016/S0889-857X(05)70044-2
- Mease PJ, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005;52: 1-19. https://doi.org/10.1016/j.jaad.2004.06.013
- Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17:401-8. https://doi.org/10.1111/j.1396-0296.2004.04043.x
- Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunium JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964;189:743-7.
- Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, doubleblind, plcebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81. https://doi.org/10.1002/art.1780270403
- Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). Oxford: The Cochrane Library; 2001.
- Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6. https://doi.org/10.1016/0002-9343(91)90667-M
- Bondeson J, Maini RN. Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J clin Pract 2001;55(3):211-6.
- Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004;50:2264-72. https://doi.org/10.1002/art.20335
- Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90. https://doi.org/10.1016/S0140-6736(00)02530-7
- Antoni C, Manger B. infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002;20: S122-5.
- Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12. https://doi.org/10.1002/art.10671
- Galadari H, Fuchs B, Lebwohl M: Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int J Dermatol 2003;42:231-7. https://doi.org/10.1046/j.1365-4362.2003.01449.x
- Zachariae H: Prevalence of joint disease in patients with psoriasis: Implications for therapy. Am J Clin Dermatol 2003;4:441-7. https://doi.org/10.2165/00128071-200304070-00001